307 related articles for article (PubMed ID: 33113997)
1. Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers.
Wu CE; Pan YR; Yeh CN; Lunec J
Biomolecules; 2020 Oct; 10(11):. PubMed ID: 33113997
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
Pignochino Y; Sarotto I; Peraldo-Neia C; Penachioni JY; Cavalloni G; Migliardi G; Casorzo L; Chiorino G; Risio M; Bardelli A; Aglietta M; Leone F
BMC Cancer; 2010 Nov; 10():631. PubMed ID: 21087480
[TBL] [Abstract][Full Text] [Related]
3. Effect of midkine on gemcitabine resistance in biliary tract cancer.
Lu Y; Yan B; Guo H; Qiu L; Sun X; Wang X; Shi Q; Bao Y
Int J Mol Med; 2018 Apr; 41(4):2003-2011. PubMed ID: 29344648
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells.
Carotenuto P; Hedayat S; Fassan M; Cardinale V; Lampis A; Guzzardo V; Vicentini C; Scarpa A; Cascione L; Costantini D; Carpino G; Alvaro D; Ghidini M; Trevisani F; Te Poele R; Salati M; Ventura S; Vlachogiannis G; Hahne JC; Boulter L; Forbes SJ; Guest RV; Cillo U; Said-Huntingford I; Begum R; Smyth E; Michalarea V; Cunningham D; Rimassa L; Santoro A; Roncalli M; Kirkin V; Clarke P; Workman P; Valeri N; Braconi C
Hepatology; 2020 Sep; 72(3):982-996. PubMed ID: 31879968
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.
Fiorini C; Cordani M; Padroni C; Blandino G; Di Agostino S; Donadelli M
Biochim Biophys Acta; 2015 Jan; 1853(1):89-100. PubMed ID: 25311384
[TBL] [Abstract][Full Text] [Related]
6. Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer.
Chen CP; Yeh CN; Pan YR; Huang WK; Hsiao YT; Lo CH; Wu CE
Biomed Pharmacother; 2023 Oct; 166():115389. PubMed ID: 37659202
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.
Ahn DH; Javle M; Ahn CW; Jain A; Mikhail S; Noonan AM; Ciombor K; Wu C; Shroff RT; Chen JL; Bekaii-Saab T
Cancer; 2016 Dec; 122(23):3657-3666. PubMed ID: 27495988
[TBL] [Abstract][Full Text] [Related]
9. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!".
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of Treg/Th17 According to Cancer Progression and Modification in Biliary Tract Cancers via Self-Producing Cytokines.
Kinoshita M; Kobayashi S; Gotoh K; Kubo M; Hayashi K; Iwagami Y; Yamada D; Akita H; Noda T; Asaoka T; Takeda Y; Tanemura M; Eguchi H; Urakawa S; Goto K; Maekawa K; Wada H; Mori M; Doki Y
Dig Dis Sci; 2020 Oct; 65(10):2937-2948. PubMed ID: 31853779
[TBL] [Abstract][Full Text] [Related]
11. BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.
Nakashima S; Kobayashi S; Nagano H; Tomokuni A; Tomimaru Y; Asaoka T; Hama N; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
Cancer Sci; 2015 May; 106(5):584-91. PubMed ID: 25736055
[TBL] [Abstract][Full Text] [Related]
12. Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers.
Arora M; Bogenberger JM; Abdelrahman AM; Yonkus J; Alva-Ruiz R; Leiting JL; Chen X; Serrano Uson Junior PL; Dumbauld CR; Baker AT; Gamb SI; Egan JB; Zhou Y; Nagalo BM; Meurice N; Eskelinen EL; Salomao MA; Kosiorek HE; Braggio E; Barrett MT; Buetow KH; Sonbol MB; Mansfield AS; Roberts LR; Bekaii-Saab TS; Ahn DH; Truty MJ; Borad MJ
Hepatology; 2022 Jan; 75(1):43-58. PubMed ID: 34407567
[TBL] [Abstract][Full Text] [Related]
13. Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route?
Kaavya J; Mahalaxmi I; Devi SM; Santhy KS; Balachandar V
J Cell Physiol; 2019 Jun; 234(6):8259-8273. PubMed ID: 30370571
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
15. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
[TBL] [Abstract][Full Text] [Related]
16. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.
Chiang NJ; Chen LT; Shan YS; Yeh CN; Chen MH
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33451059
[TBL] [Abstract][Full Text] [Related]
17. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
[TBL] [Abstract][Full Text] [Related]
18. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.
Ozaki T; Yu M; Yin D; Sun D; Zhu Y; Bu Y; Sang M
BMC Cancer; 2018 Mar; 18(1):309. PubMed ID: 29558908
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy for Biliary Tract Cancer].
Woo SM
Korean J Gastroenterol; 2017 Mar; 69(3):172-176. PubMed ID: 28329919
[TBL] [Abstract][Full Text] [Related]
20. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
